Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
Biochimica Et Biophysica Acta|July 10, 2012
Monocyte chemotactic protein-1-induced protein-1 (MCPIP1) is a novel multifunctional modulator of inflammatory reactionsJolanta Jura, Lukasz Skalniak, Aleksander KojMolecular and Cellular Biochemistry|July 5, 2014
MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κBLukasz Skalniak, Monika Dziendziel, Jolanta JuraThe FEBS Journal|April 5, 2013
Proteasome inhibitor MG-132 induces MCPIP1 expressionLukasz Skalniak, Aleksander Koj, Jolanta JuraExpert Opinion on Therapeutic Patents|March 2, 2019
A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018)Lukasz Skalniak, Ewa Surmiak, Tad A HolakThe Biochemical Journal|May 17, 2012
Effects of the novel mitochondrial protein mimitin in insulin-secreting cellsKatarzyna Hanzelka, Lukasz Skalniak, Jolanta Jura, et al.Acta Biochimica Polonica|January 17, 2014
Limited GADD45α expression and function in IL-1β toxicity towards insulin-producing cellsLukasz Skalniak, Ewa Gurgul-Convey, Katarzyna Okreglicka, et al.Protein Science : a Publication of the Protein Society|July 16, 2024
Miniprotein engineering for inhibition of PD-1/PD-L1 interactionAgnieszka Ciesiołkiewicz, Juan Lizandra Perez, Lukasz Skalniak, et al.The FEBS Journal|September 15, 2009
Regulatory feedback loop between NF-kappaB and MCP-1-induced protein 1 RNaseLukasz Skalniak, Danuta Mizgalska, Adrian Zarebski, et al.Expert Opinion on Therapeutic Patents|June 21, 2024
An updated patent review on PD-1/PD-L1 antagonists (2022-present)Wiktor Uzar, Beata Kaminska, Hubert Rybka, et al.Cancers|July 24, 2019
Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) AntagonistsJustyna Kocik, Monika Machula, Aneta Wisniewska, et al.Pageof 5